Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label, long-term safety and efficacy study of Mim8 in participants with haemophilia A with or without inhibitors
KCT0008901Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jan 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Started Jan 2024; status: active, not recruiting.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on KCT0008901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008901.